| 2025-03-26 | +0.43 % |
|
| 2025-03-25 | -1.39 % |
|
| 2025-03-24 | -0.21 % |
|
| 2025-03-21 | +0.37 % |
|
| 2025-03-20 | +0.02 % |
|
| 2025-03-19 | -0.77 % |
|
| 2025-03-18 | +0.87 % |
|
| 2025-03-17 | +0.02 % |
|
| 2025-03-13 | +0.09 % |
|
| 2025-03-12 | -1.81 % |
|
| 2025-03-11 | -1.1 % |
|
| 2025-03-07 | +0.52 % |
|
| 2025-03-06 | +0.43 % |
|
| 2025-03-05 | -0.18 % |
|
| 2025-03-04 | -1.11 % |
|
| 2025-02-26 | -1.81 % |
|
| 2025-02-25 | +1.44 % |
- Johnson & Johnson (JNJ) stock rose by 1.44% recently, attributed to increased trading volume and positive market momentum among major pharmaceutical companies as investors show heightened interest in the sector.
- Johnson & Johnson (JNJ) stock rose by 1.44% last night, likely due to positive market sentiment surrounding high-quality companies included in investment funds, such as the Betashares Global Quality Leaders ETF, which features JNJ among its top holdings.
- Johnson & Johnson's stock rose by 1.44%, closing at $162.35 due to significant trading activity, with 12,540,171 shares exchanged, well above its average volume, indicating increased investor interest in the company amid broader market trends in the healthcare sector.
|
| 2025-02-21 | +1.64 % |
|
| 2025-02-20 | +1.13 % |
|
| 2025-02-19 | +1.87 % |
- Johnson & Johnson (JNJ) stock rose by 1.87% due to positive earnings results exceeding analyst expectations, consistent institutional investor activity, and favorable ratings from brokerages, despite a recent decrease in a stake by Empire Life Investments.
- Johnson & Johnson (JNJ) stock rose by 1.87% due to positive quarterly earnings that exceeded expectations and overall strong institutional investor activity, despite a lowered stake by Covenant Asset Management.
- Johnson & Johnson's stock (NYSE: JNJ) rose by 1.87% following a mix of institutional investor activity and positive quarterly earnings results, which included a report of $2.04 EPS that surpassed analyst estimates.
- Johnson & Johnson (NYSE: JNJ) stock rose 1.87% due to increased institutional investor activity, including significant purchases by hedge funds, along with a positive quarterly earnings report exceeding analysts' expectations.
- Johnson & Johnson (JNJ) stock rose 1.87% as institutional investors, including PineStone Asset Management Inc., increased their holdings in the company, indicating strong confidence in its performance and growth potential.
|
| 2025-02-18 | +0.05 % |
- Johnson & Johnson (JNJ) stock experienced a slight increase of 0.05% due to heightened institutional investment interest, with multiple hedge funds increasing their holdings in the company, suggesting confidence in its future performance despite some analysts lowering price targets.
- Johnson & Johnson (JNJ) stock rose by 0.05% as it saw a mix of institutional investors adjusting their stakes, positive earnings results exceeding expectations, and an upcoming dividend payment, contributing to increased investor confidence.
- Johnson & Johnson (JNJ) stock saw a minor increase of 0.05% last night, likely due to its status as a well-performing dividend aristocrat, which tends to attract investors looking for stable returns through dividends even during market fluctuations.
- Johnson & Johnson's (JNJ) stock rose by 0.05% as it reported beating analyst estimates for earnings and revenue in its latest quarterly earnings, prompting positive reactions from investors and analysts, with many raising their price targets for the stock.
- Johnson & Johnson (JNJ) stock recently rose by 0.05%, attributed to positive earnings exceeding forecasts, institutional investors increasing their positions, and favorable analyst ratings that suggest a "Moderate Buy" sentiment with elevated price targets.
|
| 2025-02-12 | -0.56 % |
|
| 2025-02-11 | +1.23 % |
|
| 2025-02-07 | -0.25 % |
- Johnson & Johnson (JNJ) stock recently fell by 0.25%, influenced by mixed analyst ratings, with some firms lowering their price targets, signaling potential concerns about the stock's future performance.
- Johnson & Johnson (JNJ) stock experienced a 0.25% decline, attributed to concerns over the financial implications of Omnicom's acquisition of IPG and the potential loss of significant clients, including JNJ, which raises doubts about IPG's future revenue and stability.
- Johnson & Johnson (JNJ) stock declined by 0.25% following a series of downgrades in target prices from several analysts, reflecting a cautious outlook for the company despite reporting better-than-expected earnings for the last quarter.
- Johnson & Johnson (JNJ) stock recently declined by 0.25%, influenced by a reduction in positions by major investors and analysts lowering their price targets for the stock.
- Johnson & Johnson (JNJ) stock experienced a decline of 0.25% following Optas LLC's disclosure of a 15.6% reduction in its holdings, amidst other institutional adjustments in stock positions. The stock decrease may reflect market sensitivity to hedge fund movements and changes in ownership structures, leading to investor uncertainty.
|
| 2025-02-06 | -0.76 % |
|
| 2025-02-05 | +0.78 % |
|
| 2025-02-04 | +1.07 % |
- Johnson & Johnson (JNJ) stock rose by 1.07% partly due to positive quarterly earnings results, where the company reported higher-than-expected earnings and revenue, along with supportive actions from institutional investors and analysts raising price targets for the stock.
- Johnson & Johnson (JNJ) stock increased by 1.07% as institutional investors and hedge funds have significantly raised their stakes in the company, reflecting positive investor sentiment and confidence in its performance.
- Johnson & Johnson's (JNJ) stock rose by 1.07% likely due to significant institutional investment increases, positive quarterly earnings performance that exceeded expectations, and the announcement of a forthcoming dividend, all contributing to investor confidence in the company.
- Johnson & Johnson (JNJ) stock rose 1.07% due to positive institutional investor activities, strong quarterly earnings surpassing expectations, and an upcoming dividend payment, which collectively enhanced investor confidence.
- Johnson & Johnson (JNJ) stock rose by 1.07% due to positive investor sentiment, which could be influenced by strong institutional ownership and favorable analyst recommendations for its focus on innovative medical solutions.
|
| 2025-02-03 | -0.18 % |
|
| 2025-01-31 | -0.47 % |
|
| 2025-01-30 | +1.14 % |
|
| 2025-01-29 | +0.51 % |
|
| 2025-01-28 | -1.64 % |
|
| 2025-01-27 | +4.13 % |
|
| 2025-01-24 | +0.12 % |
|
| 2025-01-23 | +0.94 % |
|
| 2025-01-22 | -1.94 % |
- Johnson & Johnson (JNJ) stock fell by 1.94% due to a combination of institutional investor movements, recent downgrades in target prices from several research analysts, and overall market conditions.
- Johnson & Johnson's stock (JNJ) fell by 1.94% following the FDA's approval of their nasal spray, Spravato, for treating major depressive disorder, which may have sparked concerns about competition in the market for depression treatments.
- Johnson & Johnson (JNJ) stock fell by 1.94%, influenced by recent analyst downgrades in price targets, reflecting a broader sentiment shift among investors, despite steady institutional investment growth and upcoming dividend announcements.
- Johnson & Johnson (JNJ) stock fell by 1.94% primarily due to analyst downgrades and shifts in institutional investor positions, as indicated by reduced ratings and targeted price cuts from various brokerages.
- Johnson & Johnson's (JNJ) stock fell by 1.94% despite positive fourth-quarter and full-year 2024 results due to concerns over ongoing legal issues related to talc products, potential negative impacts from foreign exchange and slower medical device sales, as well as competitive pressures from generics and pricing negotiations with Medicare.
|
| 2025-01-21 | +0.76 % |
- Johnson & Johnson (JNJ) stock rose by 0.76% following significant institutional investments, including a new position by Whitaker Myers Wealth Managers and increased stakes from several other hedge funds, along with positive analyst ratings and a commitment to a healthy dividend.
- Johnson & Johnson (JNJ) stock rose 0.76% ahead of its upcoming fourth-quarter earnings report, which is anticipated to show $2 in EPS and $22.44 billion in revenues, contributing to positive investor sentiment despite a 8.88% decline over the past year.
The stock's rise may be attributed to expectations of positive earnings results and positive developments such as the approval of Spravato.
- Johnson & Johnson's stock increased by 0.76% as several institutional investors have recently adjusted their stakes in the company, alongside positive price target upgrades from various research firms, indicating strong market confidence in JNJ's long-term prospects.
- Johnson & Johnson (NYSE: JNJ) shares increased by 0.76% as institutional investors, including Smith Salley Wealth Management, made significant adjustments to their holdings, and positive analyst ratings lifted market sentiment.
The stock's rise can be attributed to strong institutional buying activity and favorable analyst upgrades, indicating confidence in the company's financial performance and future growth prospects.
- Johnson & Johnson's stock rose 0.76% following the announcement of its merger agreement with Intra-Cellular Therapies, which involves acquiring the company for $132.00 per share in cash, reflecting investor optimism about potential growth and strategic benefits from the merger.
|
| 2025-01-17 | -0.5 % |
|
| 2025-01-16 | +1.93 % |
|
| 2025-01-15 | +0.15 % |
|
| 2025-01-14 | +0.19 % |
|
| 2025-01-13 | +1.7 % |
|
| 2025-01-10 | -0.15 % |
|
| 2025-01-08 | -2.71 % |
|
| 2025-01-07 | +1.79 % |
|
| 2025-01-06 | -0.37 % |
|
| 2025-01-03 | +0.12 % |
|
| 2025-01-02 | -0.41 % |
|
| 2024-12-31 | +0.89 % |
|
| 2024-12-30 | -1.18 % |
|
| 2024-12-27 | -0.36 % |
|
| 2024-12-23 | +0.55 % |
|
| 2024-12-20 | +0.62 % |
|
| 2024-12-17 | +1.78 % |
|
| 2024-12-16 | -1.89 % |
|
| 2024-12-09 | +0.19 % |
|
| 2024-12-06 | -0.14 % |
|
| 2024-12-05 | -0.63 % |
|
| 2024-12-03 | -1.58 % |
|
| 2024-12-02 | -0.14 % |
|
| 2024-11-29 | -0.25 % |
|
| 2024-11-27 | +0.57 % |
|
| 2024-11-22 | -0.21 % |
|
| 2024-11-21 | +1.56 % |
|
| 2024-11-20 | +0.07 % |
|
| 2024-11-19 | -1.14 % |
|
| 2024-11-18 | +0.5 % |
|
| 2024-11-14 | -0.89 % |
|
| 2024-11-13 | +0.39 % |
|
| 2024-11-01 | +0.17 % |
|
| 2024-10-31 | -0.47 % |
|
| 2024-10-30 | +0.32 % |
|
| 2024-10-29 | -0.93 % |
- Johnson & Johnson (JNJ) stock fell by 0.93% after several analyst downgrades and adjusted price targets, including a reduction by Goldman Sachs and cuts from a "strong-buy" to a "hold" rating by other brokerages, which contributed to the negative sentiment around the stock.
- Johnson & Johnson (JNJ) stock dipped 0.93% after the company recently reported earnings that exceeded expectations, amid a backdrop of shifting institutional investments and analysts adjusting price targets and ratings.
The stock decline could be attributed to profit-taking or adjustments in investor sentiment following the earnings report, coupled with analysts lowering price targets, suggesting a more cautious outlook for the stock despite its solid quarterly performance.
- Johnson & Johnson (NYSE: JNJ) stock fell by 0.93% due to various institutional investors adjusting their holdings, with Salomon & Ludwin LLC significantly reducing its stake by nearly 40%, indicating possible negative sentiment or profit-taking among large shareholders.
- Johnson & Johnson (JNJ) stock dropped by 0.93% primarily due to investor actions, such as Manchester Financial Inc. reducing its holdings, mixed ratings and target price adjustments from several analysts, and a recent quarterly earnings report that, despite beating estimates, showed a decline in EPS compared to the same quarter last year.
- Johnson & Johnson (JNJ) stock fell by 0.93% despite receiving a "Moderate Buy" consensus rating from analysts due to mixed sentiments in recent evaluations, with half of the analysts maintaining a hold rating.
|
| 2024-10-28 | +0.45 % |
- Johnson & Johnson's (JNJ) stock rose by 0.45% due to increased investments in CVRx, Inc. by JNJ and other institutional investors, along with positive analysts' ratings on CVRx, indicating investor confidence in potential growth.
- Johnson & Johnson (JNJ) stock rose by 0.45% due to increased investments from institutional investors, such as GHP Investment Advisors Inc., and a positive earnings report that exceeded analysts’ expectations.
- Johnson & Johnson (JNJ) stock rose by 0.45%, attributed to increased investor confidence as Mirae Asset Global Investments significantly expanded its holdings, reflecting a trend of institutional investment growth and positive quarterly earnings results that exceeded analysts' expectations.
- Johnson & Johnson (JNJ) stock rose by 0.45%, likely driven by increased institutional investment, strong recent earnings that beat analyst expectations, and positive analyst ratings with raised price targets.
- Johnson & Johnson (JNJ) stock was up 0.45% last night likely due to increased investor confidence stemming from its recent acquisition of additional shares in CVRx, Inc., alongside positive ratings from several analysts, indicating strong market interest in the company's performance.
|
| 2024-10-25 | -1.7 % |
|
| 2024-10-24 | -1.32 % |
|
| 2024-10-23 | +1.47 % |
- Johnson & Johnson (JNJ) stock rose 1.47% after Waldron Private Wealth LLC increased its investment in the company, alongside significant interest from various institutional investors, indicative of positive sentiment towards the stock following strong quarterly earnings results that exceeded analysts' expectations.
- Johnson & Johnson (JNJ) stock rose 1.47% due to a combination of strong quarterly earnings that exceeded analyst expectations, several analysts raising their price targets on the stock, and maintaining a positive outlook with multiple buy ratings from equity research firms.
- Johnson & Johnson (JNJ) stock increased by 1.47% last night, likely due to significant investment activity from institutional investors, positive comments from brokerages raising price targets, and the company's recent strong earnings report that exceeded analyst expectations.
- The article discusses the rise of Johnson & Johnson's (JNJ) stock by 1.47% last night, which is likely attributed to increased investor confidence and buying activity, reflected in significant institutional investment activities and analysts’ favorable outlook for the company.
- Johnson & Johnson (JNJ) stock rose by 1.47% following RFP Financial Group LLC's significant increase of 56.9% in its holdings of the company's shares during the third quarter, indicating strong investor confidence and demand for the stock.
|
| 2024-10-22 | +0.38 % |
- Johnson & Johnson (JNJ) stock rose 0.38% following a successful earnings report that exceeded consensus estimates on both earnings per share and revenue, along with several institutional investors increasing their holdings in the company.
- The article highlights that Johnson & Johnson (JNJ) stock experienced a slight increase of 0.38%, and it likely rose due to positive market sentiment or specific developments related to the company, despite a previous report of a 0.1% decline.
- Johnson & Johnson (JNJ) stock rose by 0.38% due to increased institutional investment, strong quarterly earnings that exceeded analyst expectations, and favorable analyst ratings which contributed to positive investor sentiment.
- Johnson & Johnson (JNJ) stock rose by 0.38% likely due to positive earnings results exceeding analysts’ expectations, strong revenue growth, and a favorable outlook supported by increased institutional investment, despite a slight reduction in stakes from some investors.
- Johnson & Johnson (JNJ) stock rose by 0.38% following positive changes in institutional investments, analyst upgrades to price targets reflecting growing confidence in the company's earnings potential, and a recent quarterly earnings report that exceeded expectations.
|
| 2024-10-21 | -1.39 % |
- The article reports that Johnson & Johnson's stock (JNJ) fell by 1.39% following Claro Advisors LLC's significant reduction of its stake in the company by 93.3% during the third quarter.
- Johnson & Johnson (JNJ) stock fell by 1.39%, raising questions about whether it's time to sell. The decline could be attributed to market reactions, company-specific news, or broader economic factors impacting investor sentiment.
- Johnson & Johnson (JNJ) stock decreased by 1.39% amid a mixed performance in major U.S. equity indexes and growing concerns over the pace of interest rate cuts, which negatively affected sentiment in the broader market and particularly impacted sectors like real estate and health insurance.
- Johnson & Johnson (JNJ) stock fell by 1.39% due to investor sentiment being impacted by news regarding Kenvue, its spinoff company, as activist investor Starboard Value is taking a significant stake to address its underperformance, leading to concerns about JNJ's own valuation and outlook.
- Johnson & Johnson (JNJ) stock declined by 1.39% amid investor focus on Kenvue, its spun-off consumer health unit, which is facing pressure from activist investor Starboard Value to improve its stock performance after an 18% drop since its inception.
The decline in JNJ stock can be attributed to the negative sentiment surrounding Kenvue, which may have raised concerns amongst investors about JNJ's ongoing financial health and the performance of its spun-off entities.
|
| 2024-10-18 | +0.4 % |
|
| 2024-10-17 | +0.12 % |
|
| 2024-10-16 | +0.11 % |
- Johnson & Johnson's stock (JNJ) rose by 1.57% to $164.14, reflecting renewed investor confidence, likely due to strong performance metrics such as a solid dividend yield and a favorable price target.
- Johnson & Johnson (JNJ) stock experienced a slight increase of 0.11% attributed to its recent acquisition of a significant stake in Rapport Therapeutics, alongside interest from other institutional investors, suggesting a positive investor outlook and confidence in the company's growth potential in the biotechnology sector.
- The article discusses the recent 0.11% increase in Johnson & Johnson's (JNJ) stock, highlighting that such movements are often influenced by company performance, market conditions, and investor sentiment, although specific reasons for the increase were not detailed in the provided text.
- Johnson & Johnson (JNJ) stock rose by 0.11% following the announcement of Anil Kapur's appointment to the board of Nurix Therapeutics, as his extensive experience in successfully launching oncology drugs, including those developed by J&J, is perceived to positively influence Nurix’s future prospects in cancer treatment.
- The article discusses recent appointments at Goodbody Stockbrokers, including Paul Flynn as head of investment management, which aligns with the firm's growth strategy amidst a modestly improving financial outlook. Johnson & Johnson (JNJ) stock likely increased due to general market optimism or positive sentiment surrounding the company, but specific reasons for the stock's 0.11% rise are not detailed in the article.
|
| 2024-10-15 | +1.55 % |
|
| 2024-10-14 | +0.09 % |
- Johnson & Johnson's stock slightly increased by 0.09% amid a broader market rally where the S&P 500 and Dow Jones Industrial Average reached record highs, driven by strong corporate earnings and a positive sentiment despite ongoing geopolitical and election-related uncertainties.
The increase in Johnson & Johnson’s stock price can be attributed to the anticipation of their upcoming earnings report, which, alongside other companies posting better-than-expected results, has boosted investor confidence.
- Johnson & Johnson (JNJ) stock rose 0.09% amid a generally positive outlook for U.S. markets leading into corporate earnings season, with optimism fueled by recent strong performances from major financial institutions and market anticipation surrounding upcoming earnings reports from JNJ and other companies.
The increase in JNJ stock can be attributed to the overall buoyancy in Wall Street stocks, particularly in the financial sector, which reflects broader investor confidence and optimism as earnings season begins.
- Johnson & Johnson (JNJ) stock saw a slight increase of 0.09% as Wall Street anticipates a busy week of third-quarter earnings reports, including that of JNJ, amidst positive economic indicators such as a declining unemployment rate and consumer spending expectations for the holiday season.
- Johnson & Johnson (JNJ) stock rose 0.09% amidst a broader market rally characterized by all-time highs for major indices as investors responded positively to corporate earnings expectations and ongoing economic resilience, despite concerns related to upcoming elections and inflation risks.
The increase in JNJ's stock price can be attributed to overall market momentum driven by strong corporate earnings results expected this earnings season, indicating healthy economic conditions that generally boost investor confidence.
- Johnson & Johnson (JNJ) stock rose 0.09% as part of a broader upward momentum in U.S. markets driven by investor optimism around corporate earnings and the hope that the Federal Reserve's interest rate cuts will support economic growth.
|
| 2024-10-11 | +0.59 % |
|
| 2024-10-10 | -0.09 % |
|
| 2024-10-09 | +0.6 % |
- Johnson & Johnson's (JNJ) stock rose by 0.6% as institutional investors, including SL Advisors LLC and Wellington Management Group, increased their stakes in the company, indicating positive sentiment and confidence in JNJ's financial health and growth potential.
- Johnson & Johnson (JNJ) stock rose 0.6% due to a mix of institutional trading activity, positive earnings performance, and favorable analyst ratings, despite some target price adjustments.
- Johnson & Johnson (JNJ) stock rose by 0.6% due to Country Trust Bank increasing its holdings by 4.3%, indicating investor confidence in the company's performance.
- Johnson & Johnson (JNJ) stock rose by 0.6%, likely due to a combination of positive earnings performance, upgrades from analysts, and continued interest from institutional investors, with the company reporting strong quarterly earnings and maintaining a solid dividend yield.
- Johnson & Johnson's stock rose 0.3% after the Royal Bank of Canada increased its price target for the stock from $175.00 to $178.00, indicating a positive outlook.
|
| 2024-10-08 | +0.1 % |
|
| 2024-10-07 | -0.47 % |
|
| 2024-10-04 | -0.13 % |
|
| 2024-10-03 | -0.42 % |
- The Johnson & Johnson (JNJ) stock was down by 0.42%, reflecting broader market trends and possibly investor reactions to company news or macroeconomic factors affecting the healthcare sector.
- Johnson & Johnson (JNJ) stock fell by 0.42% due to concerns related to the pharmaceutical industry's advertising practices for COVID-19 vaccines, particularly in light of investigations revealing that major vaccine manufacturers, including Pfizer, exploited regulatory loopholes to avoid disclosing critical information about their vaccines in advertisements.
- Johnson & Johnson's stock (JNJ) fell 0.3% on Thursday, reaching a low of $160.27 and experiencing significantly reduced trading volume, which could indicate decreased investor interest or market concern. The stock's drop may be attributed to a variety of factors, including broader market trends, company-specific news, or investor sentiment impacting trading activity.
- The article discusses how Pfizer and other pharmaceutical companies effectively marketed their COVID-19 vaccines without adequate disclosures about their emergency use authorization status, raising ethical concerns.
Johnson & Johnson (JNJ) stock fell by -0.42%, which could be attributed to overall market trends, investor sentiment regarding vaccine effectiveness, or specific concerns about the regulatory and legal scrutiny facing vaccine manufacturers, including JNJ.
- The article discusses the performance of various stocks across different sectors over the past three decades, highlighting that not all top performers are from the technology sector, while mentioning that Johnson & Johnson (JNJ) stock recently declined by 0.42%. The decline in JNJ's stock could be attributed to broader market trends affecting healthcare stocks or specific company news impacting investor sentiment.
|
| 2024-10-02 | -0.51 % |
|
| 2024-10-01 | -0.04 % |
- The article discusses the appointment of Dr. Makoto Sugita as the new President and Chief Medical Officer at Nxera Pharma, which may have impacted investor sentiment towards Johnson & Johnson (JNJ), leading to a slight decline in its stock price by 0.04% as it could indicate a talent shift away from JNJ towards competitive biopharmaceutical firms.
- Johnson & Johnson (JNJ) stock experienced a slight decline of 0.04% due to various market factors, even as Truist Financial Corp increased its stake in the company by 4.9% in the second quarter.
The decline in JNJ's stock price may be attributed to broader market trends, investor sentiment, or specific company news affecting stock performance.
- Johnson & Johnson (JNJ) shares experienced a slight decline of 0.04%, closing at $162.20 after a day of unusually low trading volume. The drop in stock price may be attributed to reduced trading activity, which often reflects investor hesitation or uncertainty.
- Johnson & Johnson's (JNJ) stock was down by 0.04% due to various market factors affecting investor sentiment, which might include economic indicators, industry competition, or company-specific concerns.
|
| 2024-09-30 | +0.41 % |
|
| 2024-09-27 | +0.01 % |
|
